Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (“HAE”) and acquired angioedema due to C1 inhibitor deficiency (“AAE-C1INH”), announced today the pricing of an underwritten offering of 3,874,664 of its ordinary shares at a price of $29.68 per share. All shares in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 581,199 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $115 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about May 11, 2026, subject to satisfaction of customary closing conditions.

Morgan Stanley, Leerink Partners, Cantor and Wells Fargo Securities are acting as joint book-running managers.

The shares are being offered by Pharvaris pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (the “SEC”). The offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement.